Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Liabilities (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Total Liabilities for 6 consecutive years, with $369.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 4.87% year-over-year to $369.8 million, compared with a TTM value of $369.8 million through Dec 2025, up 4.87%, and an annual FY2025 reading of $369.8 million, up 4.87% over the prior year.
  • Total Liabilities was $369.8 million for Q4 2025 at Xeris Biopharma Holdings, roughly flat from $371.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $371.1 million in Q3 2025 and bottomed at -$44.4 million in Q1 2021.
  • Average Total Liabilities over 5 years is $270.8 million, with a median of $319.5 million recorded in 2023.
  • The sharpest move saw Total Liabilities skyrocketed 1330.25% in 2022, then rose 0.85% in 2025.
  • Year by year, Total Liabilities stood at $209.1 million in 2021, then skyrocketed by 43.13% to $299.3 million in 2022, then increased by 10.04% to $329.4 million in 2023, then rose by 7.07% to $352.7 million in 2024, then rose by 4.87% to $369.8 million in 2025.
  • Business Quant data shows Total Liabilities for XERS at $369.8 million in Q4 2025, $371.1 million in Q3 2025, and $354.0 million in Q2 2025.